Journal article

Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects

Michael Wodkowski, Marie Hudson, Susanna Proudman, Jennifer Walker, Wendy Stevens, Mandana Nikpour, Shervin Assassi, Maureen D Mayes, Solene Tatibouet, Mianbo Wang, Murray Baron, Marvin J Fritzler

Autoimmunity | TAYLOR & FRANCIS LTD | Published : 2015


OBJECTIVE: Autoantibodies directed against the two principal antigens of the human exosome complex, PM75 and PM100, are present in systemic sclerosis (SSc) sera and have been associated with myositis and calcinosis. However, there is a paucity of data on the clinical correlates of these autoantibodies separately and in the absence of other SSc-specific antibodies. The aim of this study was to assess the clinical correlates of monospecific anti-PM75 and anti-PM100 in SSc. METHODS: A tri-nation cohort of 1574 SSc subjects was formed, clinical variables were harmonized and sera were tested for anti-PM75 and anti-PM100 antibodies using a line immunoassay. RESULTS: Forty-eight (3.0%) subjects had..

View full abstract


Awarded by Canadian Institutes of Health Research (CIHR)

Awarded by NHMRC

Awarded by NIH/NIAMS


Funding Acknowledgements

The CSRG received funds and/or gifts in kind from the Canadian Institutes of Health Research (CIHR) (grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclerodermie Quebec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA, USA), Euroimmun (Lubeck, Germany), Fonds de la recherche en sante du Quebec (FRSQ), the Canadian Arthritis Network (CAN), the Arthritis Society Research Chair (University of Calgary) and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Dr. Hudson is funded by the Fonds de la recherche en Sante du Quebec. Dr. Nikpour holds an NHMRC research fellowship (APP1071735). ASIG receives unrestricted grants from Actelion, Pfizer and GSK, and is also supported by Scleroderma Australia. Dr. Assassi is funded by the NIH/NIAMS K23AR061436. Dr. Mayes is funded by NIH/NIAMS AR055258. The GENISOS cohort receives funding from DoDW81XWH-13-1-0452. The funding sources had no role in the design of the study, analysis of the data, preparation of the manuscript and decision to submit for publication.